ReInnervate is developing new and innovative ways to manage the growth and function of cultured cells. Its technologies have multiple applications and will be particularly relevant to the control of stem cell differentiation.
ReInnervate is a spin-out biotechnology company emanating from research conducted at Durham University. The Company was established in July 2002 to commerialise technology developed by its founding scientist working in the field of stem cell biology and developmental neuroscience.
ReInnervate specialises in the development of enabling technologies to facilitate research into cell growth and function in vitro with immediate applications to research and development in the biotechnology and pharmaceutical sectors. Aspects of the Company's research are also suitable for development into diagnostic tools and have potential therapeutic applications.
Currently, ReInnervate either directly or indirectly employs around 10 staff, including 6 PhD's with many years combined experience in cell biology and physical science. The Company operates from state-of-the-art laboratories within the University and has access to modern research facilities.
The company has raised >£0.5M from various sources to support its initial research and development programmes and is seeking additional inward investment to bring its technologies to market.
